 |
 |
|
| Startseite |
| Impressum |
| Datenschutz |
 | |
| Volume 36, 1 October 2005 | 10/2005 |
| SPOT ON | |
ASCOT Study: are new antihypertensives really any better? | |
 |
Doubts about advantages of atorvastatin (SORTIS) in acute coronary syndrome |
| NEW ON THE MARKET | |
Anticonvulsive Zonisamide (ZONEGRAN) | |
| THERAPIES FROM A CRITICAL VIEW POINT | |
N-acetylcysteine (e.g. FLUIMUCIL) without influence on natural course of COLD | |
| a-t READERS' QUESTIONS AND COMMENTS | |
Beware of ORTHOKIN: factors produced by blood cells for osteoarthritis | |
| IN BRIEF | |
Hexavalent vaccine HEXAVAC off market | |
| CURRENT ADR NETWORK REPORT | |
Thrombosis by quetiapine (SEROQUEL) | |
| QUALITY CHECK | |
Allopurinol, amoxicillin, and naproxen products | |
| SIDE EFFECTS | |
Suicidality by isotretinoin (e.g. ROACCUTAN) | |
|
© arznei-telegramm 10/2005 | ||
 |  | |